Novartis AG
NVSEF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001114448
No open-market purchases or sales by Novartis AG insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $6.28M in total; no superinvestor holds it.
Other share classesNVS
Q4 2021 vs. Q3 2021
How the institutions holding Novartis AG changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 4 | 1 | 2 | −1 |
| Shares | 37.3K | 850 | 35.1K | −1.29K (−3.5%) |
| Value | $3.07M | $70.0K | $3.09M | +$89.0K (+3.0%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (0)
Institutions that held Novartis AG at the end of Q4 2021 but not at the end of Q3 2021.
None.
Sold out (1)
Institutions that held Novartis AG at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| ARK Investment Management LLCSuperinvestorARK Invest | 3,621 | $298.0K |
Not filed for Q4 2021 yet (1)
Institutions that held Novartis AG at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Filbrandt Wealth Management, LLC | 850 | $70.0K |